Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE Trial

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 2, 2017, Pages 315-322

  Pasch, Andreas ^a   Block, Geoffrey A ^b   Bachtler, Matthias ^a   Smith, Edward R ^c   Jahnen Dechent, Wilhelm ^d   Arampatzis, Spyridon ^a   Chertow, Glenn M ^e   Parfrey, Patrick ^f   Ma, Xiaoye ^g   Floege, Juergen ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b Denver Nephrologists   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Health Sciences Centre St John's   (Canada)

^g AMGEN INC   (United States)

Author keywords

Angina, unstable; Bicarbonates; Calcification propensity; Calciprotein particles; Cholesterol, HDL; Cinacalcet hydrochloride; Cpp; Creatinine; Evolve; Follow up studies; Heart failure; Hematologic tests; Hemodialysis; Hospitalization; Humans; Myocardial infarction; Phosphates; Prospective studies; Renal dialysis; Serum albumin; T50

Indexed keywords

ALBUMIN; BICARBONATE; CINACALCET; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; CALCIMIMETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CALCIFICATION PROPENSITY; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; FEMALE; FOLLOW UP; HEART FAILURE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POST HOC ANALYSIS; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS; BLOOD; CALCINOSIS; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; HEART INFARCTION; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANGINA, UNSTABLE; CALCIMIMETIC AGENTS; CALCINOSIS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CINACALCET HYDROCHLORIDE; FEMALE; HEART FAILURE; HEMATOLOGIC TESTS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 85021757738     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04720416     Document Type: Article

References (47)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 [Suppl 3]: S112-S119, 1998
3. Shah DS, Polkinghorne KR, Pellicano R, Kerr PG: Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton) 13: 667-671, 2008
4. Huang JC, Chen SC, Su HM, Chang JM, Hwang SJ, Chen HC: Performance of the Framingham risk score in patients receiving hemodialysis. Nephrology (Carlton) 18: 510-515, 2013
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM:Mineralmetabolism,mortality, andmorbidity inmaintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
6. Floege J, Gillespie IA, Kronenberg F, Anker SD, Gioni I, Richards S, Pisoni RL, Robinson BM, Marcelli D, Froissart M, Eckardt KU: Development and validation of a predictivemortality risk score froma European hemodialysis cohort. Kidney Int 87: 996-1008, 2015
7. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Dias Curto J, Malluche HH: Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 4: 450-455, 2009
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl (113): S1-S130, 2009
9. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
11. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
12. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20: 381-387, 2009
13. Ribeiro S, Ramos A, Brandaõ A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remédio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998
14. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl JMed 342: 1478-1483, 2000
15. Civilibal M, Caliskan S, Kurugoglu S, Candan C, Canpolat N, Sever L, Kasapcopur O, Arisoy N: Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediatr Nephrol 24: 555-563, 2009
16. Ohtake T, Ishioka K, Honda K, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Hidaka S, Kobayashi S: Impact of coronary artery calcification in hemodialysis patients: Risk factors and associations with prognosis. Hemodial Int 14: 218-225, 2010
17. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001
18. Abdelmalek JA, Stark P, Walther CP, Ix JH, Rifkin DE: Associations between coronary calcification on chest radiographs and mortality in hemodialysis patients. Am J Kidney Dis 60: 990-997, 2012
19. Liu S, Zhang DL, Guo W, Cui WY, Liu WH: Left ventricular mass index and aortic arch calcification score are independent mortality predictors of maintenance hemodialysis patients. Hemodial Int 16: 504-511, 2012
20. Górriz JL, Molina P, Cerverón MJ, Vila R, Bover J, Nieto J, Barril G, Martínez-Castelao A, Fernández E, Escudero V, Piñera C, Adragao T, Navarro-Gonzalez JF, Molinero LM, Castro-Alonso C, Pallardó LM, Jamal SA: Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol 10: 654-666, 2015
21. Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23: 1744-1752, 2012
22. Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG, Pasch A: Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 25: 339-348, 2014
23. Keyzer CA, de Borst MH, van den Berg E, Jahnen-Dechent W, Arampatzis S, Farese S, Bergmann IP, Floege J, Navis G, Bakker SJ, van Goor H, Eisenberger U, Pasch A: Calcification propensity and survival among renal transplant recipients. J AmSoc Nephrol 27: 239-248, 2016
24. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482-2494, 2012
25. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS: Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant 27: 2872-2879, 2012
26. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2: 898-905, 2007
27. D’Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB: Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med 9: 1501-1515, 1990
28. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172, discussion 207-212, 2008
29. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8: 475-486, 1997
30. Spiegel DM, Raggi P, Smits G, Block GA: Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant 22: 3568-3572, 2007
31. Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, Bos WJ, Kooman JP, Dekker FW, Ketteler M, Schurgers LJ, Krediet RT, Korevaar JC; NECOSAD Study Group: Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 26: 1662-1669, 2011
32. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 1489-1496, 2004
33. Oka M, Ohtake T, Mochida Y, Ishioka K, Maesato K, Moriya H, Hidaka S, Kobayashi S: Correlation of coronary artery calcification with pre-hemodialysis bicarbonate levels in patients on hemodialysis. Ther Apher Dial 16: 267-271, 2012
34. Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 661-671, 2004
35. Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2: 1241-1248, 2007
36. de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW; Netherlands Cooperative Study on the Adequacy of Dialysis-II Study Group: Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 19: 127-135, 2009
37. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118: 1748-1757, 2008
38. Boskey AL, Posner AS: Conversion of amorphous calcium phosphate to microcrystalline hydroxyapatite. A pH-dependent, solution-mediated, solid-solid conversion. J Phys Chem 77: 2313-2317, 1973
39. Meyer JL, Eanes ED: A thermodynamic analysis of the amorphous to crystalline calcium phosphate transformation. Calcif Tissue Res 25: 59-68, 1978
40. Heiss A, DuChesne A, Denecke B, Gröötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem278: 13333-13341, 2003
41. Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, Schäfer C, Jahnen-Dechent W: Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 283: 14815-14825, 2008
42. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Iseki K, Tsubakihara Y, Isaka Y; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy: Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: A cohort study. PLoS One 9: e116273, 2014
43. Dahle DO, Åsberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A: Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients. Am J Transplant 16: 204-212, 2016
44. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M; Alberta KidneyDiseaseNetwork: Cause of death in patients with reduced kidney function. J Am Soc Nephrol 26: 2504-2511, 2015
45. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose andmembrane flux inmaintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
46. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
47. St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51: 445-454, 2008